跨国药企密集投资中国，聚集消费级市场

Group 1 - Major multinational pharmaceutical companies are announcing new investment plans in China, targeting the vast health consumer market with projects ranging from weight loss drugs to oral health [2] - Eli Lilly plans to invest $3 billion in China over the next 10 years to build production capacity for GLP-1 class drugs, including diabetes and weight loss injections, as well as future oral weight loss medications [2] - The global health company Heliant is accelerating its expansion in China, planning to invest £65 million (approximately 600 million RMB) to establish a new oral health factory in Shanghai, with China contributing over £1 billion (approximately 9.2 billion RMB) to its revenue annually [2] Group 2 - Pierre Fabre Laboratories emphasizes its commitment to increasing investments in oncology and dermatological skincare in China, which is identified as a key overseas market and a strategic growth pillar [3] - The company expects that by 2025, e-commerce will account for about two-thirds of its skincare business in China, achieving double-digit year-on-year growth [3] - Pierre Fabre has established an innovation R&D center in Shanghai in 2023, anticipating that around 15% of its sales by 2026 will come from locally developed innovations [4] Group 3 - The CEO of Pierre Fabre expressed surprise at the rapid development of health industry technologies in China, noting the faster adoption of emerging technologies like AI compared to many other regions [4] - The company is seeking collaborations with Chinese startups to integrate AI and other technologies into its medical value chain [4] - Recent improvements in China's business environment and healthcare reforms are seen as supportive measures for multinational companies like Pierre Fabre, facilitating ongoing investment and innovation [4]